Novel glutamatergic modulators for the treatment of mood disorders: current status
The efficacy of standard antidepressants is limited for many patients with mood disorders
such as major depressive disorder (MDD) and bipolar depression, underscoring the urgent …
such as major depressive disorder (MDD) and bipolar depression, underscoring the urgent …
Understanding the mechanism of action and clinical effects of neuroactive steroids and GABAergic compounds in major depressive disorder
AJ Cutler, GW Mattingly, V Maletic - Translational Psychiatry, 2023 - nature.com
The pathophysiology of major depressive disorder (MDD) is thought to result from impaired
connectivity between key brain networks. Gamma-aminobutyric acid (GABA) is the key …
connectivity between key brain networks. Gamma-aminobutyric acid (GABA) is the key …
Zuranolone for the treatment of postpartum depression
KM Deligiannidis, S Meltzer-Brody… - American Journal of …, 2023 - Am Psychiatric Assoc
Objective: Postpartum depression (PPD) is a common perinatal complication with adverse
maternal and infant outcomes. This study investigated the efficacy and safety of zuranolone …
maternal and infant outcomes. This study investigated the efficacy and safety of zuranolone …
Effect of zuranolone vs placebo in postpartum depression: a randomized clinical trial
KM Deligiannidis, S Meltzer-Brody… - JAMA …, 2021 - jamanetwork.com
Importance Postpartum depression (PPD) is one of the most common medical complications
during and after pregnancy, negatively affecting both mother and child. Objective To …
during and after pregnancy, negatively affecting both mother and child. Objective To …
GABAkines–Advances in the discovery, development, and commercialization of positive allosteric modulators of GABAA receptors
Positive allosteric modulators of γ-aminobutyric acid-A (GABA A) receptors or GABAkines
have been widely used medicines for over 70 years for anxiety, epilepsy, sleep, and other …
have been widely used medicines for over 70 years for anxiety, epilepsy, sleep, and other …
[HTML][HTML] Recent advances in understanding/management of premenstrual dysphoric disorder/premenstrual syndrome
L Tiranini, RE Nappi - Faculty reviews, 2022 - ncbi.nlm.nih.gov
Premenstrual syndrome (PMS) and premenstrual dysphoric disorder (PMDD) are common
disorders of the luteal phase of the menstrual cycle and are characterized by moderate to …
disorders of the luteal phase of the menstrual cycle and are characterized by moderate to …
Is postpartum depression different from depression occurring outside of the perinatal period? A review of the evidence
Whether a major depressive episode occurring in the postpartum period (ie, postpartum
depression [PPD]) is sufficiently distinct from major depressive episodes occurring at other …
depression [PPD]) is sufficiently distinct from major depressive episodes occurring at other …
Brexanolone (Zulresso): finally, an FDA-approved treatment for postpartum depression
JG Powell, S Garland, K Preston… - Annals of …, 2020 - journals.sagepub.com
Objective: To review the safety and efficacy of brexanolone for the treatment of moderate to
severe postpartum depression (PPD). Data Sources: A literature search through PubMed …
severe postpartum depression (PPD). Data Sources: A literature search through PubMed …
Preclinical and clinical pharmacology of brexanolone (allopregnanolone) for postpartum depression: A landmark journey from concept to clinic in neurosteroid …
DS Reddy, RH Mbilinyi, E Estes - Psychopharmacology, 2023 - Springer
This article describes the critical role of neurosteroids in postpartum depression (PPD) and
outlines the landmark pharmacological journey of brexanolone as a first-in-class …
outlines the landmark pharmacological journey of brexanolone as a first-in-class …
[HTML][HTML] Lower urinary tract symptoms in depression: a review
DJ Anderson, A Aucoin, CR Toups… - Health psychology …, 2023 - ncbi.nlm.nih.gov
Abstract Lower Urinary Tract Symptoms (LUTS) are frequently present in the general
population as patients age with approximately a third of individuals experiencing LUTS …
population as patients age with approximately a third of individuals experiencing LUTS …